Breathing a sigh of relief

With the GLP-1 market continuing to explode many including us here at Diabetic Investor had high hopes for the Intarcia exenatide micropump. Hopes which were dashed as the FDA has now rejected the device twice which likely put an end to the device and may well put an end to Intarcia. The company put out a statement yesterday which said;

“We are extremely disappointed with the receipt of a Complete Response Letter (CRL) from the FDA. We remain steadfast in our belief that ITCA 650 holds important potential as a new treatment option for people managing type 2 diabetes . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.